Search research articles
Contact Us
Filters
Showing results (291-300 of 310) with videos related to
Page
of 31
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study
Gee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
Clinical Lung Cancer
|
April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Microbiology Spectrum
|
July 7, 2025
Heterogeneity among <i>Mycobacterium avium</i> complex species isolated from pulmonary infection in Taiwan
Hsiu-Mei Lin, Chin-Chung Shu, Chun-Hao Chen, et al.
Anticancer Research
|
March 9, 2012
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations
Ming-Mo Hou, Shiu-Feng Huang, Han-Pin Kuo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2019
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.
Oncotarget
|
July 25, 2016
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
Kuo-Hsuan Hsu, Jeng-Sen Tseng, Chih-Liang Wang, et al.
Emerging Microbes & Infections
|
June 17, 2020
SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East
Yu-Nong Gong, Kuo-Chien Tsao, Mei-Jen Hsiao, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 310) with videos related to
Sort By:
Page
of 31
Lung Cancer (Amsterdam, Netherlands)
|
February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study
Gee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
Clinical Lung Cancer
|
April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Microbiology Spectrum
|
July 7, 2025
Heterogeneity among <i>Mycobacterium avium</i> complex species isolated from pulmonary infection in Taiwan
Hsiu-Mei Lin, Chin-Chung Shu, Chun-Hao Chen, et al.
Anticancer Research
|
March 9, 2012
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations
Ming-Mo Hou, Shiu-Feng Huang, Han-Pin Kuo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2019
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.
Oncotarget
|
July 25, 2016
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
Kuo-Hsuan Hsu, Jeng-Sen Tseng, Chih-Liang Wang, et al.
Emerging Microbes & Infections
|
June 17, 2020
SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East
Yu-Nong Gong, Kuo-Chien Tsao, Mei-Jen Hsiao, et al.
Page
of 31